Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00096083|
Recruitment Status : Completed
First Posted : November 9, 2004
Last Update Posted : October 23, 2013
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving an hepatic arterial infusion of melphalan together with hepatic perfusion works in treating patients with unresectable liver cancer.
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Drug: isolated perfusion Drug: melphalan||Phase 2|
- Determine the response rate and duration of response in patients with unresectable primary or metastatic liver cancer treated with intrahepatic arterial infusion of melphalan with venous filtration via peripheral hepatic perfusion.
- Determine the patterns of recurrence in patients treated with this regimen.
- Determine progression-free and overall survival of patients treated with this regimen.
- Evaluate the safety and tolerability of this regimen in these patients.
- Assess the filter characteristics including melphalan pharmacokinetics and filtration of cytokines and clotting factors during and after treatment.
OUTLINE: Patients are stratified according to primary tumor histology (neuroendocrine tumor vs primary hepatic malignancy vs adenocarcinoma of gastrointestinal or other origin).
Patients undergo peripheral isolated hepatic perfusion in which a catheter is placed via the groin into the hepatic artery and another into the hepatic vein. Patients then receive melphalan as an intrahepatic arterial infusion over 15-30 minutes. Treatment repeats approximately every 3-8 weeks for up to 6 total infusions in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 4 months for 1 year, and then periodically thereafter.
PROJECTED ACCRUAL: A total of 105 patients will be accrued for this study within 4-5 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver|
|Study Start Date :||September 2004|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||August 2012|
|Active Comparator: Melphalan Administration PHP||Drug: isolated perfusion Drug: melphalan|
- To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies [ Time Frame: Survivial ]
- To determine the patterns of recurrence following percutaneous hepatic perfusions (PHP) with melphalan [ Time Frame: Survival ]
- To determine the progression free and overall survival in patients with hepatic malignancies following this therapy [ Time Frame: Survivial ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00096083
|United States, Maryland|
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office|
|Bethesda, Maryland, United States, 20892-1182|
|Principal Investigator:||Marybeth Hughes, MD||NCI - Surgery Branch|